Product Information
| Property | Description |
|---|---|
| Product Name | Anti-mouse/human PPARγ Recombinant Monoclonal Antibody |
| Antibody ID | XM0049 |
| Target Protein | Peroxisome proliferator-activated receptor gamma |
| Target Protein Short Name | PPARγ |
| UniProt Accession | P37231-1 (human), P37231-2 (human), P37231-3 (human), P37238-1 (mouse), P37238-2 (mouse) |
| Molecular Weight | Human: 57.6 kDa, 54.7 kDa, 21.6 kDa; Mouse: 57.6 kDa, 54.5 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Mouse, human |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | DLSVMEDHSHSFDIKPFTTVDF |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C |
| Research Use | For research use only. Not for diagnostic or therapeutic applications |
Product Background
Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated nuclear receptor that plays essential roles in adipogenesis, lipid metabolism, glucose homeostasis, inflammation, insulin sensitivity, and metabolic regulation. PPARγ is widely studied in obesity research, diabetes, cancer biology, fibrosis, inflammation, and transcriptional regulation.
XM0049 recognizes conserved regions shared between mouse and human PPARγ proteins, enabling cross-species detection in Western blot applications.
Antibody Development
XM0049 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the PPARγ epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot detection of endogenous full-length PPARγ protein
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc-only control protein.
Validation conditions:
- Well 1: Fc control protein
- Well 2: Epitope-Fc fusion protein
- Detection substrate: TMB
Note:
ELISA validation confirms binding to epitope-Fc fusion antigen. Full-length protein binding in solution has not been tested by ELISA.
Western Blot Validation – Recombinant Fusion Protein
Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while minimal binding was observed against MBP control protein.
Validation conditions:
- Lane 1: MBP control protein
- Lane 2: MBP-epitope fusion protein
- Standard reducing Western blot
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous full-length PPARγ protein under reducing conditions.
Validated samples:
- Human HEK293T (293T) cells
- Mouse eWAT tissue
- Mouse liver tissue
Observed bands:
- Besides bands with the expected molecular weight range for endogenous PPARγ isoforms, additional bands may represent alternatively spliced isoforms, post-translationally modified species, degradation products, or protein-associated complexes.
The antibody recognizes both mouse and human PPARγ proteins due to strong epitope sequence conservation between species.
Detection condition:
- Standard reducing Western blot
- HRP-conjugated anti-mouse secondary antibody















